- Tivic Health Systems, Inc. (TIVC, Financial) shareholders have approved key proposals for the company's strategic transformation.
- Lisa Wolf has been appointed as the permanent Chief Financial Officer of Tivic.
- The company is expanding its biopharmaceutical focus with the commercialization of Entolimod for acute radiation syndrome and neutropenia.
Tivic Health Systems, Inc. (TIVC), a leader in immunotherapeutics, has announced the approval of critical proposals by its shareholders during the recent annual meeting. These proposals enable the issuance of equity in line with Tivic's worldwide exclusive license agreement for Entolimod™ and Entolasta™, targeting conditions such as acute radiation syndrome and neutropenia. These approvals were required under Nasdaq listing rules, marking a pivotal step in Tivic's strategic transformation.
CEO Jennifer Ernst emphasized the successful establishment of a strong foundation for Tivic's expansion into the biopharmaceutical sector. She highlighted significant customer interest in Entolimod's applications for national defense, specifically as a treatment for acute radiation syndrome. The rights to use Entolimod for treating neutropenia, a market projected to reach nearly $21 billion globally by 2032, have also been secured.
In a leadership update, it was announced that Lisa Wolf, who has served as Interim Chief Financial Officer for nine months, will now permanently assume the CFO role. CEO Ernst praised Wolf's contributions to Tivic's financial architecture during this transformative phase. Additionally, former Chief Scientific Officer Blake Gurfein will transition to a consulting role, continuing to support the Vagus Nerve Stimulation program, which includes product and intellectual property development.
Tivic Health Systems continues to innovate in addressing underserved medical conditions through biochemical and bioelectric therapies, with its leading biopharma product candidate, Entolimod™, having received FDA Fast Track and Orphan Drug designation.
